Brevitest Technologies, founded with the mission to revolutionize early-stage disease detection, focuses on developing portable, automated medical devices. Their core product is a point-of-care analyzer that performs enzyme-linked immunosorbent assays (ELISAs) in under ten minutes using customizable disposable cartridges. This technology is designed to detect and quantify peptides, proteins, antibodies, and hormones in biological samples, aiming to replace traditional, time-consuming laboratory diagnostics with swift and accurate point-of-care solutions.

Notable individuals affiliated with Brevitest Technologies include experts in medical device innovation and diagnostics. The company has garnered attention for its significant achievements in reducing the need for autopsies by providing real-time, cost-effective diagnostic tools for coroners and medical examiners. Brevitest's impact is evident in its contribution to alleviating the national shortage of pathology services, thereby enhancing the efficiency and effectiveness of medical examinations and early disease detection.